Bristol Myers Squibb & BioNTech
Independent Medical Education
Request for Educational Support (RFE)

Date	05/04/2026
RFE Requestor Information	Name: Maria Deutsch Title: Global Medical Oncology, Medical Education E-mail: maria.deutsch@bms.com Name: Fiona Zhu Title: Senior Director, Medical Excellence E-mail: fiona.zhu@biontech.de
RFE Code	RFE-26-ONC-103
Therapeutic Area	Oncology – Triple Negative Breast Cancer (TNBC)
Area of Interest	Novel and emerging immunomodulators for the treatment of triple negative breast cancer (TNBC)
Educational Design	Bristol Myers Squibb & BioNTech are interested in supporting an innovative, comprehensive educational initiative that includes the following: • An on-demand, web-based enduring activity translated in English, Mandarin, Spanish, Italian, and German. Knowledge and competency-based objective outcome measures according to Moore's Level 4 are required.
Intended Audience (may include, but not limited to)	Targeted to medical oncologists, nurses, NPs, PAs, pharmacists, and other healthcare professionals involved in the care of patients with breast cancer.
Budget/Budget Range	The anticipated program is expected to be achieved with a budget of no more than $200,000. Single and multi-supported initiatives will be considered. *Significant or major updates to the medical content (e.g., regulatory status changes, primary data releases, etc.) are expected for enduring online activities outlined in this RFE.
Accreditation	ACCME, ACPE, CCNE, ECCME, and others as appropriate to the audience(s) of various countries and learners being educated.

Geographic Coverage	United States Ex-US regions: China, Spain, Italy, and Germany Please follow local accredited continuing medical education guidance and compliance. Please include in the grant proposal each country's HCP accreditation requirements. **Please note**: UK and French healthcare professional learners will need to be geoblocked from participating in the educational activity that is granted IME support.
Deadline for Submission (Date and Time)	Friday, 06/12/2026 EOB 5pm EST

Background:

Major advances have been made in the last decade with oncology treatments, with innovation supporting the development of novel mechanisms and better patient outcomes.[1] However, there remains a significant unmet need, including in certain solid tumors, such as TNBC.[1] Often, solid tumors exhibit substantial heterogeneity in antigen expression, leading to resistance against single-targeted therapies.[2] Bispecific antibodies (BsAbs) are able to simultaneously target two distinct antigens, overcoming tumor heterogeneity and providing broader tumor coverage.[2] BsAbs have been evaluated in combination with chemotherapy for first-line treatment of TNBC and are being explored alongside antibody-drug conjugates.[3,4] Among these, Trop-2-directed ADCs (Trop2 ADCs) are a modality for solid tumors with high Trop-2 expression, and their combination with bsAbs is also being actively studied in trials.[4,5,6]

Education Needs:

Medically accurate, fair-balanced learning programs are required to maximize transparency and minimize clinician bias in the provision of medical education. Applying evidence-based scientific knowledge significantly contributes to professional competencies of HCPs and improves patient outcomes.

These activities will ensure timely and effective communication of the latest science and clinical trial data.

The following educational needs should be addressed through this educational program:

- Describe the current unmet needs in TNBC management and discuss how novel and emerging immunomodulators may address these challenges
- Explain the mechanism of action of emerging immunomodulator under investigation for the treatment of TNBC, and review the latest clinical evidence on their safety and efficacy
- Compare the therapeutic benefits and challenges of novel immunomodulators versus monoclonal antibody therapies (e.g., PD-(L)1-based therapies), and identify key

considerations for their clinical integration, including safety, efficacy, and patient selection

References

1. Miao H, Fang Y, Pan C, et al. Transforming the landscape of cancer treatment with seven promising novel therapies: evolution and future perspectives. Medicine Plus. 2025;2(2):100087. doi:10.1016/j.medp.2025.100087
2. Guidi L, Etessami J, Valenza C, Valdivia A, Meric-Bernstam F, Felip E, Curigliano G. Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances. Am Soc Clin Oncol Educ Book. 2025;45(3):e473148. doi:10.1200/EDBK-25-473148
3. BioNTech and Bristol Myers Squibb present first global phase 2 data for PD-L1xVEGF-A bispecific antibody pumitamig showing encouraging efficacy in advanced triple-negative breast cancer. Bristol Myers Squibb News. Published 2025. Accessed February 17, 2026. https://news.bms.com/news/details/2025/BioNTech-and-Bristol-Myers-Squibb-Present-First-Global-Phase-2-Data-for-PD-L1xVEGF-A-Bispecific-Antibody-Pumitamig-Showing-Encouraging-Efficacy-in-Advanced-Triple-Negative-Breast-Cancer/default.aspx
4. DualityBio Inc. A Phase 1/2a, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305/BNT325 in Subjects With Advanced or Metastatic Solid Tumors. ClinicalTrials.gov. Identifier: NCT05438329. Accessed March 24, 2026. https://clinicaltrials.gov/study/NCT05438329
5. Liu X, Ma L, Li J, et al. Trop2-targeted therapies in solid tumors: advances and future directions. Theranostics. 2024;14(9):3674-3692. Published 2024 Jun 11. doi:10.7150/thno.98178
6. Jabbarzadeh Kaboli P, Shabani S, Sharma S, Partovi Nasr M, Yamaguchi H, Hung MC. Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates. Am J Cancer Res. 2022;12(4):1671-1685. Published 2022 Apr 15.

Grant Proposals should include, but not be limited to, the following information:

- **Executive Summary: The Executive Summary should consist of 1-2 pages and highlight the key areas as described below.**

- **Needs Assessment/Gaps/Barriers**: Needs assessment should be referenced and demonstrate an understanding of the specific gaps and barriers of the target audiences. The needs assessment must be independently developed and validated by the educational provider through triangulation.

- **Target Audience and Audience Generation**: Target audience for educational program must be identified within the proposal. In addition, please describe methods for

reaching target audience(s) and any unique recruitment methods that will be utilized. The anticipated or estimated participant reach should also be included, with a breakdown for each modality included in the proposal, as applicable (e.g., number of participants for the live activity, the live webcast, and enduring activity).

- **Learning Objectives**: The learning objectives must be written in terms of what the learner will achieve as a result of attending. The objectives must be clearly defined, measurable, attainable, and address the identified gaps and barriers.

- **Program Evaluation and Outcomes Reporting:** Description of the approach to evaluate the quality of the educational program. Describe methods used for determining the impact of the educational program on closing identified healthcare gaps.
    - Please refer to "Guidance for Outcomes Report" (on the BMS grants website) for a detailed explanation of preferred outcomes reporting methods and timelines.
    - Remember that knowledge, performance and competency based outcome measures according to Moore's Levels 4 & 5 are required. Level 6 outcomes are highly favored and recommended when possible.

- **Educational Design and Methods**: Describe the approach used to address knowledge, competence, and performance gaps that underlie identified healthcare gaps. The proposal should include strategies that ensure reinforcement of learning through use of multiple educational interventions and include practice resources and tools, as applicable.

- **Communication and Publication Plan**: Provide a description of how the provider will communicate the progress and outcomes of the educational program to the supporter. It is highly recommended to describe how the results of the activity will be presented, published, or disseminated.

- **Innovation**: Describe how this project is innovative and engages the learners to improve knowledge, competence and/or performance. Further describe how this project might build on existing work, pilot projects or ongoing projects developed either by your institution or other institutions related to this topic.

- **Budget**: Detailed budget with rationale of expenses, including breakdown of costs, content cost per activity, out-of-pocket cost per activity, and management cost per activity.

Note: The accredited provider and, if applicable, the medical education partner (MEP) or other third party executing the activities, are expected to comply with current ethical codes and regulations. They must have a conflict-of-interest policy in place to identify and resolve all conflicts of interest from all contributors and staff involved in developing the content of the activity prior to delivery of the program, and must have a separate company

providing/accrediting independent medical education if they are also performing promotional activities.

If your organization wishes to submit an educational grant request, please use the online application available on the Bristol Myers Squibb Independent Medical Education website.
http://www.bms.com/responsibility/grantsandgiving